Challenges in combating arboviral infections

DOI: https://doi.org/10.1038/s41467-024-47161-3

IF: 16.6

2024-04-19

Nature Communications

Abstract:Arboviral infections are major public health threats, with 100 million people estimated to get sick annually from dengue infection alone. Globally, the risk of arboviruses is likely to further increase both within, and outside of, affected regions due to a combination of factors including climate change, human mobility, and other societal factors. Despite the availability of vaccines for some arbovirus infections, there is a lack of specific antiviral treatment options. Professor Johan Neyts at the University of Leuven, Belgium, has been working on developing antiviral strategies for more than 30 years. His current research focuses on developing antiviral drugs and vaccines against emerging and neglected viruses many of which are arboviruses. In this Q&A, he discusses the risks associated with vector-borne virus infections, challenges in developing efficient drugs for treatment, and current promising efforts to address these challenges.

multidisciplinary sciences